Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer

NCT07358689 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

120

Enrollment

OTHER

Sponsor class

Conditions

NSCLC

Interventions

DRUG: Toripalimab (240mg day1, Q3W*3cycle)
DRUG: Diphenhydramine
DRUG: Platinum-based chemotherapy

Sponsor

Tianjin Medical University Cancer Institute and Hospital